HRP20190603T1 - 2-supstituirani spojevi cefema - Google Patents
2-supstituirani spojevi cefema Download PDFInfo
- Publication number
- HRP20190603T1 HRP20190603T1 HRP20190603TT HRP20190603T HRP20190603T1 HR P20190603 T1 HRP20190603 T1 HR P20190603T1 HR P20190603T T HRP20190603T T HR P20190603TT HR P20190603 T HRP20190603 T HR P20190603T HR P20190603 T1 HRP20190603 T1 HR P20190603T1
- Authority
- HR
- Croatia
- Prior art keywords
- acid
- pharmaceutically acceptable
- compound
- infection
- acceptable salt
- Prior art date
Links
- -1 cephem compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 241000894006 Bacteria Species 0.000 claims 9
- 208000015181 infectious disease Diseases 0.000 claims 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 108090000204 Dipeptidase 1 Proteins 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 102000006635 beta-lactamase Human genes 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 2
- 229940071870 hydroiodic acid Drugs 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 229910052744 lithium Inorganic materials 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- 229910017604 nitric acid Inorganic materials 0.000 claims 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- 241000589291 Acinetobacter Species 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 241001453380 Burkholderia Species 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 241000588923 Citrobacter Species 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims 1
- 206010014568 Empyema Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 241000588914 Enterobacter Species 0.000 claims 1
- 241000305071 Enterobacterales Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- 241000192125 Firmicutes Species 0.000 claims 1
- 241000606790 Haemophilus Species 0.000 claims 1
- ZQICGTYUOSVFMN-UHFFFAOYSA-N Iselin Natural products CC1=C(COc2c3ccoc3cc3oc(=O)ccc23)CC(C)(C)CC1 ZQICGTYUOSVFMN-UHFFFAOYSA-N 0.000 claims 1
- 241000588748 Klebsiella Species 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 1
- 241000588621 Moraxella Species 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 208000001388 Opportunistic Infections Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 241000588769 Proteus <enterobacteria> Species 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 241000607720 Serratia Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000122971 Stenotrophomonas Species 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 206010048038 Wound infection Diseases 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 235000011054 acetic acid Nutrition 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 238000011203 antimicrobial therapy Methods 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 229910052788 barium Inorganic materials 0.000 claims 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 229960002510 mandelic acid Drugs 0.000 claims 1
- 229960003194 meglumine Drugs 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 102000020235 metallo-beta-lactamase Human genes 0.000 claims 1
- 108060004734 metallo-beta-lactamase Proteins 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 229960003085 meticillin Drugs 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 235000006408 oxalic acid Nutrition 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/48—Methylene radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/48—Methylene radicals, substituted by hetero rings
- C07D501/50—Methylene radicals, substituted by hetero rings with the 7-amino radical acylated by an aliphatic carboxylic acid, which is substituted by hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
- C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
- C07D505/16—Nitrogen atoms
- C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
- C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (13)
1. Spoj, naznačen time što je:
;
ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je:
.
3. Spoj, naznačen time što je:
;
ili njegova farmaceutski prihvatljiva sol.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što je:
.
5. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 3, naznačen time što se farmaceutski prihvatljivu sol bira između soli dobivenih s litijem, natrijem, kalijem, kalcijem, barijem, magnezijem, cinkom, željezom, amonijakom, trimetilaminom, trietilaminom, dicikloheksilaminom, etanolaminom, dietanolaminom, trietanolaminom, megluminom, dietanolaminom, etilendiaminom, piridinom, pikolinom, kinolinom, aminokiselinom, klorovodičnom kiselinom, sumpornom kiselinom, dušičnom kiselinom, ugljičnom kiselinom, bromovodičnom kiselinom, fosfornom kiselinom, jodovodičnom kiselinom, mravljom kiselinom, octenom kiselinom, propionskom kiselinom, trifluoroctenom kiselinom, limunskom kiselinom, mliječnom kiselinom, vinskom kiselinom, oksalnom kiselinom, maleinskom kiselinom, fumarnom kiselinom, bademovom kiselinom, glutarnom kiselinom, jabučnom kiselinom, benzojevom kiselinom, ftalnom kiselinom, askorbinskom kiselinom, benzensulfonskom kiselinom, p-toluensulfonskom kiselinom, metansulfonskom kiselinom ili etansulfonskom kiselinom.
6. Spoj u skladu s patentnim zahtjevom 5, naznačen time što se farmaceutski prihvatljivu sol bira između soli dobivenih s litijem, natrijem, kalijem, aminokiselinom, klorovodičnom kiselinom, sumpornom kiselinom, dušičnom kiselinom, ugljičnom kiselinom, bromovodičnom kiselinom, fosfornom kiselinom ili jodovodičnom kiselinom.
7. Farmaceutski pripravak, naznačen time što sadrži spoj, ili njegovu farmaceutski prihvatljivu sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 6, kao i najmanje jedan ili više farmaceutski prihvatljivih pomoćne tvari.
8. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačeni time što su namijenjeni upotrebi u antimikrobnoj terapiji.
9. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačeni time što su namijenjeni upotrebi u terapiji protiv infekcije Gram-negativnim bakterijama.
10. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačeni time što su namijenjeni upotrebi u terapiji protiv infekcije Gram-negativnim bakterijama koje proizvode β-laktamazu.
11. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačeni time što su namijenjeni upotrebi u terapiji protiv infekcije:
– Gram-negativnim bakterijama koje se bira između Gram-negativnih bakterija iz skupine enterobakterija primjerice E. coli, Klebsiella, Serratia, Enterobacter, Citrobacter, Morganella, Providencia ili Proteus;
– Gram-negativnim bakterijama koje koloniziraju dišni sustav, koje se bira između bakterija Haemophilus ili Moraxella;
– Gram-negativnim bakterijama koje ne fermentiraju glukozu, koje se bira između bakterija Pseudomonas aeruginosa, Pseudomonas koji nije P. aeruginosa, Stenotrophomonas, Burkholderia ili Acinetobacter;
– Gram-negativnim bakterijama otpornim na više lijekova, koje se bira između Gram-negativne bakterije koje proizvode metalo-β-laktamazu tipa klase B; i
– bakterijama koje proizvode β-laktamazu proširenog spektra (ESBL).
12. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačeni time što su namijenjeni upotrebi u terapiji protiv infekcije Gram-pozitivnim bakterijama, koje se bira između Staphylococcus aureus otpornog na meticilin (MRSA) ili Streptococcus pneumoniae otpornog na penicilin (PRSP).
13. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačeni time što su namijenjeni upotrebi u liječenju bakterijske infekcije, koja je infekcija dišnih puteva, infekcija mokraćnog sustava, infekcija dišnog sustava, septična infekcija, nefritis, kolecistitis, infekcija usne šupljine, endokarditis, pneumonija, mijelitis membrane koštane srži, upala srednjeg uha, enteritis, empijem, infekcija rane ili oportunistička infekcija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719523P | 2012-10-29 | 2012-10-29 | |
| PCT/IB2013/002423 WO2014068388A1 (en) | 2012-10-29 | 2013-10-29 | 2 substituted cephem compounds |
| EP13820853.3A EP2917223B1 (en) | 2012-10-29 | 2013-10-29 | 2 substituted cephem compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190603T1 true HRP20190603T1 (hr) | 2019-05-31 |
Family
ID=49955387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190603TT HRP20190603T1 (hr) | 2012-10-29 | 2019-03-28 | 2-supstituirani spojevi cefema |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US20150299223A1 (hr) |
| EP (1) | EP2917223B1 (hr) |
| JP (1) | JP6316830B2 (hr) |
| KR (1) | KR20150081428A (hr) |
| CN (2) | CN107652310A (hr) |
| AR (1) | AR093261A1 (hr) |
| AU (2) | AU2013340469B2 (hr) |
| BR (2) | BR112015009460A2 (hr) |
| CA (1) | CA2889746A1 (hr) |
| CL (1) | CL2015001084A1 (hr) |
| CR (1) | CR20150224A (hr) |
| CY (1) | CY1121721T1 (hr) |
| DK (1) | DK2917223T3 (hr) |
| EA (1) | EA031881B1 (hr) |
| ES (1) | ES2717923T3 (hr) |
| HK (1) | HK1214826A1 (hr) |
| HR (1) | HRP20190603T1 (hr) |
| HU (1) | HUE042664T2 (hr) |
| IL (1) | IL238149A (hr) |
| LT (1) | LT2917223T (hr) |
| MA (1) | MA38039A1 (hr) |
| ME (1) | ME03359B (hr) |
| MX (1) | MX365534B (hr) |
| MY (1) | MY176987A (hr) |
| NZ (1) | NZ628527A (hr) |
| PE (1) | PE20151204A1 (hr) |
| PH (2) | PH12015500914A1 (hr) |
| PL (1) | PL2917223T3 (hr) |
| PT (1) | PT2917223T (hr) |
| RS (1) | RS58611B1 (hr) |
| SG (2) | SG10201703589TA (hr) |
| SI (1) | SI2917223T1 (hr) |
| TR (1) | TR201904001T4 (hr) |
| TW (1) | TWI625333B (hr) |
| UA (1) | UA117666C2 (hr) |
| UY (1) | UY35103A (hr) |
| WO (1) | WO2014068388A1 (hr) |
| ZA (1) | ZA201502174B (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2015120084A (ru) * | 2012-10-29 | 2016-12-27 | Сионоги Энд Ко., Лтд. | Способы получения промежуточных соединений для 2-алкилцефемовых соединений |
| US20150344502A1 (en) * | 2012-12-26 | 2015-12-03 | Shionogi & Co., Ltd. | Cephem compound |
| JP6377570B2 (ja) * | 2014-04-28 | 2018-08-22 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | ２−置換セフェム化合物を含有する医薬組成物 |
| DK3190115T3 (da) * | 2014-09-04 | 2021-10-25 | Shionogi & Co | Salt af cephalosporinderivat, krystallinsk fast form deraf og fremgangsmåde til fremstilling deraf |
| EP3189049B1 (en) * | 2014-09-05 | 2024-03-20 | Genentech, Inc. | Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer |
| WO2016036873A1 (en) | 2014-09-05 | 2016-03-10 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| CN104529735A (zh) * | 2014-12-08 | 2015-04-22 | 苏州施亚生物科技有限公司 | 一种1-(5-溴-4-氯-2-氟苯基)-乙酮的合成方法 |
| WO2016112298A1 (en) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | Pyridazinone derivatives and their use in the treatment of cancer |
| CN107709314A (zh) | 2015-06-11 | 2018-02-16 | 巴斯利尔药物国际股份公司 | 外排泵抑制剂及其治疗性用途 |
| US10759739B2 (en) | 2015-06-11 | 2020-09-01 | University of Pittsburgh—of the Commonwealth System of Higher Education | P62-ZZ small molecule modulators |
| US9765026B2 (en) * | 2015-08-28 | 2017-09-19 | Scinopharm Taiwan, Ltd. | Forms of apremilast and the process of making the same |
| JP6967000B2 (ja) | 2015-12-10 | 2021-11-17 | ナエジャ−アールジーエム ファーマシューティカルズ ユーエルシー | セフェム系化合物、それらの生成および使用 |
| AU2018219226A1 (en) | 2017-02-07 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| CN106966914B (zh) * | 2017-05-04 | 2019-02-22 | 无锡捷化医药科技有限公司 | 一种5-溴-4-氯-2-氨基苯乙酮的制备方法 |
| CN112055595A (zh) | 2018-01-22 | 2020-12-08 | 恩多塞特公司 | Car t细胞的使用方法 |
| CN108892639B (zh) * | 2018-08-13 | 2021-05-14 | 云南民族大学 | 一种高效环保制备喹诺酮类化合物的方法 |
| CN111171052B (zh) * | 2020-03-04 | 2021-09-03 | 深圳尚诺生物科技有限公司 | 一种盐酸头孢吡肟的合成方法 |
| JP2024503656A (ja) * | 2021-01-12 | 2024-01-26 | 上海森▲輝▼医▲葯▼有限公司 | セファロスポリン系抗菌化合物及びその調製方法 |
| CN113698365A (zh) * | 2021-08-30 | 2021-11-26 | 成都大学 | 一种头孢地尔侧链的制备方法 |
| CN116514679A (zh) * | 2023-04-03 | 2023-08-01 | 南京工业大学 | 一种以廉价高效的硝酸季铵盐作为氧化剂的钯催化sp2和sp3碳氢键烯基化方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3487079A (en) * | 1966-01-14 | 1969-12-30 | Bristol Myers Co | Certain alpha-amino bicyclic beta-lactam carboxylic acids |
| US3926983A (en) * | 1974-08-30 | 1975-12-16 | Squibb & Sons Inc | 3-Heterothio{8 (alkoxycarbonyl)thioacetyl{9 cephalosporanic derivatives |
| US4268509A (en) | 1978-07-10 | 1981-05-19 | Fujisawa Pharmaceutical Co., Ltd. | New cephem compounds and processes for preparation thereof |
| JPS5511600A (en) * | 1978-07-10 | 1980-01-26 | Fujisawa Pharmaceut Co Ltd | Cephem compound, its salt, their preparation and remedy and prophylactic for microbism containing mainly the same |
| JPS56118085A (en) | 1980-02-25 | 1981-09-16 | Takeda Chem Ind Ltd | 2-methylcephalosporin derivative and its preparation |
| GB8816519D0 (en) | 1987-07-23 | 1988-08-17 | Ici Plc | Antibiotic compounds |
| JPH0228185A (ja) | 1988-04-14 | 1990-01-30 | Tanabe Seiyaku Co Ltd | セファロスポリン化合物及びその合成中間体 |
| PH25965A (en) | 1988-06-06 | 1992-01-13 | Fujisawa Pharmaceutical Co | New cephem compounds which have antimicrobial activities |
| GB8813945D0 (en) | 1988-06-13 | 1988-07-20 | Fujisawa Pharmaceutical Co | New cephem compounds & process for preparation thereof |
| GB8817653D0 (en) | 1988-07-25 | 1988-09-01 | Fujisawa Pharmaceutical Co | New cephem compounds & processes for preparation thereof |
| US5143910A (en) | 1989-09-07 | 1992-09-01 | Shionogi & Co., Ltd. | Piperaziniocephalosporins |
| GB9005246D0 (en) | 1990-03-08 | 1990-05-02 | Fujisawa Pharmaceutical Co | New cephem compounds and processes for preparation thereof |
| US5095012A (en) * | 1990-08-23 | 1992-03-10 | Bristol-Myers Squibb Company | Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof |
| GB9111406D0 (en) | 1991-05-28 | 1991-07-17 | Fujisawa Pharmaceutical Co | New cephem compounds and processes for preparation thereof |
| GB9118672D0 (en) | 1991-08-30 | 1991-10-16 | Fujisawa Pharmaceutical Co | New cephem compounds and processes for preparation thereof |
| EP0620225B1 (en) | 1993-04-16 | 2002-11-13 | Basilea Pharmaceutica AG | Cephalosporin derivatives |
| EP0838465A1 (en) | 1996-10-22 | 1998-04-29 | F. Hoffmann-La Roche Ag | Pyridinium-substituted (lactamylvinyl)cephalosporin derivatives, their preparation and their use as antibiotics |
| EP0841339B1 (en) | 1996-11-06 | 2007-02-21 | Basilea Pharmaceutica AG | Vinylpyrrolidinon cephalosporin derivatives |
| JP2003078440A (ja) | 2001-08-30 | 2003-03-14 | Kyocera Corp | 高周波スイッチ回路 |
| TW200305422A (en) | 2002-03-18 | 2003-11-01 | Shionogi & Co | Broad spectrum cefem compounds |
| JP4557859B2 (ja) | 2005-09-29 | 2010-10-06 | 富士通株式会社 | 周波数分割多重送受信装置及び送受信方法 |
| EP1994035A1 (en) | 2006-03-16 | 2008-11-26 | Astellas Pharma Inc. | Cephem compounds and use as antimicrobial agents |
| ME02666B (me) * | 2008-10-31 | 2017-06-20 | Shionogi & Co | Cefalosporin sa kateholskom grupom |
| WO2011125966A1 (ja) | 2010-04-05 | 2011-10-13 | 塩野義製薬株式会社 | 擬似カテコール基を有するセフェム化合物 |
| WO2011125967A1 (ja) * | 2010-04-05 | 2011-10-13 | 塩野義製薬株式会社 | カテコール基を有するセフェム化合物 |
| WO2011136268A1 (ja) | 2010-04-28 | 2011-11-03 | 塩野義製薬株式会社 | 新規なセフェム誘導体 |
| US8785467B2 (en) * | 2010-09-30 | 2014-07-22 | Merck Sharp & Dohme Corp. | Alkoxy pyrimidine PDE10 inhibitors |
| EP2703406A4 (en) * | 2011-04-28 | 2015-08-05 | Shionogi & Co | NOVEL CEPHEM COMPOUND HAVING THE CATÉCHOL STRUCTURE OR A STRUCTURE CLOSE TO CATÉCHOL |
| US9242999B2 (en) * | 2011-06-27 | 2016-01-26 | Shionogi & Co., Ltd. | Cephem compound having pyridinium group |
| TWI547496B (zh) | 2011-10-04 | 2016-09-01 | 葛蘭素集團公司 | 抗菌化合物 |
| JPWO2013051597A1 (ja) * | 2011-10-04 | 2015-03-30 | 塩野義製薬株式会社 | カテコール基を有するセフェム誘導体 |
| RU2015120084A (ru) | 2012-10-29 | 2016-12-27 | Сионоги Энд Ко., Лтд. | Способы получения промежуточных соединений для 2-алкилцефемовых соединений |
-
2013
- 2013-10-25 UY UY0001035103A patent/UY35103A/es unknown
- 2013-10-29 EA EA201590844A patent/EA031881B1/ru not_active IP Right Cessation
- 2013-10-29 PL PL13820853T patent/PL2917223T3/pl unknown
- 2013-10-29 HU HUE13820853A patent/HUE042664T2/hu unknown
- 2013-10-29 MA MA38039A patent/MA38039A1/fr unknown
- 2013-10-29 EP EP13820853.3A patent/EP2917223B1/en active Active
- 2013-10-29 UA UAA201505213A patent/UA117666C2/uk unknown
- 2013-10-29 JP JP2015538583A patent/JP6316830B2/ja active Active
- 2013-10-29 CN CN201710928528.9A patent/CN107652310A/zh active Pending
- 2013-10-29 US US14/439,219 patent/US20150299223A1/en not_active Abandoned
- 2013-10-29 TR TR2019/04001T patent/TR201904001T4/tr unknown
- 2013-10-29 CA CA2889746A patent/CA2889746A1/en not_active Abandoned
- 2013-10-29 NZ NZ628527A patent/NZ628527A/en not_active IP Right Cessation
- 2013-10-29 PE PE2015000527A patent/PE20151204A1/es unknown
- 2013-10-29 SG SG10201703589TA patent/SG10201703589TA/en unknown
- 2013-10-29 SI SI201331401T patent/SI2917223T1/sl unknown
- 2013-10-29 TW TW102139095A patent/TWI625333B/zh not_active IP Right Cessation
- 2013-10-29 WO PCT/IB2013/002423 patent/WO2014068388A1/en active Application Filing
- 2013-10-29 BR BR112015009460A patent/BR112015009460A2/pt not_active IP Right Cessation
- 2013-10-29 ME MEP-2019-61A patent/ME03359B/me unknown
- 2013-10-29 MX MX2015005429A patent/MX365534B/es active IP Right Grant
- 2013-10-29 DK DK13820853.3T patent/DK2917223T3/en active
- 2013-10-29 RS RS20190449A patent/RS58611B1/sr unknown
- 2013-10-29 SG SG11201502540RA patent/SG11201502540RA/en unknown
- 2013-10-29 MY MYPI2015701345A patent/MY176987A/en unknown
- 2013-10-29 PT PT13820853T patent/PT2917223T/pt unknown
- 2013-10-29 ES ES13820853T patent/ES2717923T3/es active Active
- 2013-10-29 LT LTEP13820853.3T patent/LT2917223T/lt unknown
- 2013-10-29 AU AU2013340469A patent/AU2013340469B2/en not_active Ceased
- 2013-10-29 CN CN201380068743.6A patent/CN104884460B/zh not_active Expired - Fee Related
- 2013-10-29 AR ARP130103941A patent/AR093261A1/es unknown
- 2013-10-29 BR BR122016025225-6A patent/BR122016025225A2/pt not_active Application Discontinuation
- 2013-10-30 KR KR1020157010699A patent/KR20150081428A/ko not_active Application Discontinuation
-
2015
- 2015-03-30 ZA ZA2015/02174A patent/ZA201502174B/en unknown
- 2015-04-02 IL IL238149A patent/IL238149A/en active IP Right Grant
- 2015-04-23 PH PH12015500914A patent/PH12015500914A1/en unknown
- 2015-04-24 CL CL2015001084A patent/CL2015001084A1/es unknown
- 2015-04-29 CR CR20150224A patent/CR20150224A/es unknown
-
2016
- 2016-03-11 HK HK16102833.9A patent/HK1214826A1/zh not_active IP Right Cessation
-
2017
- 2017-02-02 AU AU2017200717A patent/AU2017200717A1/en not_active Abandoned
- 2017-04-18 US US15/490,220 patent/US10174053B2/en not_active Expired - Fee Related
- 2017-04-24 PH PH12017500755A patent/PH12017500755A1/en unknown
-
2019
- 2019-03-28 HR HRP20190603TT patent/HRP20190603T1/hr unknown
- 2019-04-08 CY CY20191100387T patent/CY1121721T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190603T1 (hr) | 2-supstituirani spojevi cefema | |
| IN2014MN01882A (hr) | ||
| JP2013253094A5 (hr) | ||
| MX2018005382A (es) | Compuestos de biaril-monobactam y metodos de uso de los mismos para el tratamiento de infecciones bacterianas. | |
| JP2017510580A5 (hr) | ||
| RU2014117658A (ru) | Антибактериальные соединения | |
| TW201713633A (en) | Metallo-beta-lactamase inhibitors | |
| IL278571B2 (en) | Antibacterial compounds | |
| JP2011530534A5 (hr) | ||
| EA201691766A1 (ru) | Органические соединения, являющиеся монобактамами, для лечения бактериальных инфекций | |
| PH12020550107A1 (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| HRP20130928T1 (hr) | C7-fluor supstituirani spojevi tetraciklina | |
| JP2016534121A5 (hr) | ||
| WO2013036783A3 (en) | Methods for treating intrapulmonary infections | |
| JP2017519768A5 (hr) | ||
| JP2015531378A5 (hr) | ||
| WO2013055258A3 (ru) | Применение глутарилгистамина для лечения заболеваний дыхательных путей | |
| JP2013523761A5 (hr) | ||
| JP2020536966A5 (hr) | ||
| SA518390825B1 (ar) | مضاد حيوي جديد فعال من أمينو جلايكوسيد للبكتيريا المضادة لعقاقير متعددة | |
| BR112018011670A2 (pt) | compostos antibacterianos | |
| WO2009066917A3 (en) | 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivative or its salt, process for the preparation thereof and pharmaceutical composition comprising the same | |
| JP2018523675A5 (hr) | ||
| WO2017029602A3 (en) | Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system | |
| HRP20200986T1 (hr) | Inhibitori beta-laktamaze |